Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, permanent Healthcare Common Procedure Coding System J-code by the Centers for Medicare & Medicaid Services. Effective April 1, healthcare providers may use the permanent J-code, J9161 when submitting claims for Lymphir. J-codes are unique identifiers utilized by U.S. government and commercial payers, as well as physicians and their office staff, to streamline the billing and reimbursement process for infused therapies and certain other treatments.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- CTXR Upcoming Earnings Report: What to Expect?
- Citius Pharmaceuticals announces $3M registered direct offering priced ATM
- Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25
- Citius Oncology to explore strategic alternatives
- Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz